Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$2.7 million.

  • X4 Pharmaceuticals' Change in Account Payables fell 55758.62% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year decrease of 89797.3%. This contributed to the annual value of -$286000.0 for FY2024, which is 12317.67% down from last year.
  • X4 Pharmaceuticals' Change in Account Payables amounted to -$2.7 million in Q3 2025, which was down 55758.62% from -$3.4 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Change in Account Payables high stood at $3.9 million for Q4 2022, and its period low was -$3.4 million during Q2 2025.
  • For the 5-year period, X4 Pharmaceuticals' Change in Account Payables averaged around $100947.4, with its median value being $4000.0 (2024).
  • As far as peak fluctuations go, X4 Pharmaceuticals' Change in Account Payables crashed by 300000.0% in 2022, and later soared by 6180000.0% in 2025.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Change in Account Payables stood at $1.9 million in 2021, then surged by 109.89% to $3.9 million in 2022, then tumbled by 79.31% to $808000.0 in 2023, then tumbled by 90.35% to $78000.0 in 2024, then tumbled by 3502.56% to -$2.7 million in 2025.
  • Its Change in Account Payables was -$2.7 million in Q3 2025, compared to -$3.4 million in Q2 2025 and $2.5 million in Q1 2025.